Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Inclusion Criteria: * Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded. * Subjects with non MSI-H / dMMR metastatic colorectal cancer(CRC) (Stage IV) * Subjects must have failed at least two lines of prior treatment, which must include a fluoropyrimidine, oxaliplatin and irinotecan. * Subjects must not have been treated with Fruquitinib or any anti-PD-1 inhibitors. * Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.is necessary. * Adequate bone marrow, liver, cardiac and renal function as assessed by the laboratory required by protocol. * Assigned informed consent. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. * Life expectancy of at least 3 months. * Subjects must complete the treatment and follow-up on schedule according to the research plan. * No brain metastasis, no spinal cord compression. * Subjects agree to use blood samples for study analysis. * Women of childbearing age must be negative in pregnancy test and willing to take effective contraceptive measures during the study period. Exclusion Criteria: * Subjects are severe malnutrition or need tube feeding. * Radiotherapy or surgery has been performed within 30 days before treatment. * Previous treatment with anti-PD-1 / PD-L1 inhibitor and / or fruquitinib. * Other malignant tumors within 2 years and without cure (except for cured basal cell carcinoma of skin and carcinoma in situ of cervix); * Subjects have active autoimmune system diseases、systemic hormone therapy or anti autoimmune drug therapy. * Subjects with immunodeficiency or receiving systemic steroid therapy (prednisone \> 10 mg / day or other equivalent drugs) or other forms of immunosuppressive therapy 7 days before the first dose of combination therapy in this study; * Subjects with active infection and still need systemic treatment 7 days before the first dose of therapy in this study. * Subjects with uncontrollable systemic diabetes. * Subjects with interstitial lung disease, non infectious pneumonia or pulmonary fibrosis; * Subjects who have received allogeneic organ or stem cell transplantation in the past. * Subjects allergic to the drugs or related components involved in this study. * Are participating in other interventional clinical studies. * The previous anti-tumor related adverses do not return to grade 1 in CTCAE before the first combination therapy. * Subjects who have uncontrolled hypertension by drugs, that is, systolic blood pressure ≥ 140 mmHg and / or diastolic blood pressure ≥ 90 mmHg. * Thrombotic or hemorrhagic tendency or history within 60 days before the first medication, regardless of the severity. * Any serious or unstable medical condition、mental illness or known active alcohol or drug abuse or dependence.